Erasca, Inc. 是一家臨床階段的精準腫瘤學公司,總部位於加州聖地牙哥,目前擁有103名全職員工。該公司於2021年7月15日上市。公司專注於發現、開發和商業化針對RAS/MAPK信號通路驅動癌症患者的療法。Erasca已建立業界首屈一指的RAS/MAPK通路專注型研發管線,其項目涵蓋多種治療模式,並圍繞三項治療策略:靶向RAS/MAPK通路中的關鍵上游和下游信號節點、直接靶向RAS,以及靶向因治療反應而產生的逃逸途徑。其研發管線包括一項處於臨床階段的項目(廣譜RAF抑制劑)、兩項IND申辦前階段的項目(廣譜RAS分子膠和廣譜KRAS抑制劑),以及另一項處於發現階段的項目(EGFR D2/D3雙向抗體)。公司的主要候選藥物為naporafenib,目前已啟動SEACRAFT-2關鍵性III期臨床試驗,針對NRAS基因突變(NRASm)黑色素瘤患者。
How did ERAS's recent EPS compare to expectations?
The most recent EPS for Erasca Inc is $-0.6, 超出預期 expectations of $-0.21.
How did Erasca Inc ERAS's revenue perform in the last quarter?
Erasca Inc revenue for the last quarter is $-0.6
What is the revenue estimate for Erasca Inc?
According to 11 of Wall street analyst, the revenue estimate of Erasca Inc range from $0.0 to $0.0
What's the earning quality score for Erasca Inc?
Erasca Inc has a earning quality score of A-/60.59778. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Erasca Inc report earnings?
Erasca Inc next earnings report is expected in 2026-08-09
What are Erasca Inc's expected earnings?
Erasca Inc expected earnings is $0.0, according to wall-street analysts.
Did Erasca Inc beat earnings expectations?
Erasca Inc recent earnings of $0.0 未達預期 expectations.